• A Stronger, More Disciplined Future for Emerging Biopharma

    Clinical Research News | With the close of 2025 came the end of a prolonged biotech winter marked by reduced funding, massive job cuts, investor skepticism, and initial public offering slowdown. The experience, while painful, helped mature the biopharma industry with operational discipline and a new playbook for how to make the case with investors moving forward.

    Jan 13, 2026

  • New In-Ear EEG Platform Opens Door to Real-World Neurological Data Collection

    Clinical Research News | A newly FDA-cleared in-ear electroencephalogram (EEG) device could significantly alter how neurological conditions are studied, screened, and monitored outside traditional clinical settings. Paris-based Naox Technologies announced at CES 2026 in Las Vegas that its medical-grade Naox Link system has received U.S. Food and Drug Administration 510(k) clearance.

    Jan 12, 2026

  • The Scope of Things: Raising the Bar for Evidence Generation in Clinical Research

    Clinical Research News | As clinical research faces mounting pressure to generate real-world evidence faster and more efficiently, non-interventional studies may be a useful tool to achieve this. Yet, they have been historically underutilized.

    Jan 8, 2026

  • Trendspotting: Embracing AI, DEI Changes, Restrategizing Research Sites

    Clinical Research News | To kick off 2026, we spoke with industry experts and leaders in the Clinical Research News community about what they expect and look forward to in the new year. More than ever before, artificial intelligence took center stage.

    Jan 6, 2026

  • Top Stories of 2025: AI in Clinical Research, Pharmacy Recruitment, Pragmatic Trials

    Clinical Research News | In clinical research, AI was the hottest topic this year, with the Food & Drug Administration, big pharma, and researchers exploring ways generative AI can help with drug discovery, the clinical trials process, and the regulatory landscape. But clinical trials are still a personal venture, and other stories topped the list highlighting the person-to-person interaction necessary for trial success.

    Dec 29, 2025

  • Follow the Money: AL Amyloidosis Trial, Cancer Medicine Programs, Focal Refractory Epilepsy Treatment

    Clinical Research News | Protego Biopharma will advance their lead candidate, PROT-001, into a pivotal clinical trial for AL amyloidosis; BlossomHill will expand their cancer medicine programs; EpilepsyGTx will advance its lead program EPY201 through Phase 1/2a clinical trials for focal refractory epilepsy; and more.

    Dec 23, 2025

  • New Members at NORD, Pangea, AstraZeneca Collaboration, Predicting Human Toxicity

    Clinical Research News | The National Organization for Rare Disorders (NORD) adds seven new members its national NORD Rare Disease Centers of Excellence Network; Pangaea announces a multi‑year strategic collaboration with AstraZeneca; Sanford Burnham Prebys Medical Discovery Institute plan to develop computational models to predict human toxicity; and more.

    Dec 22, 2025

  • Clinical Trials Evolve: Mixed FSP/FSO Models Add Agility and Expertise

    Clinical Research News | For every day of delay in a clinical trial, sponsors lose $500,000 in prescription drug sales and incur $40,000 in direct clinical trial costs, according to the Tufts Center for the Study of Drug Development. These numbers show why speed and control matter more than ever, as drug development continues getting more complex and expensive.

    Dec 19, 2025

  • Clinical Trials Evolve: Mixed FSP/FSO Models Add Agility and Expertise

    Clinical Research News | For every day of delay in a clinical trial, sponsors lose $500,000 in prescription drug sales and incur $40,000 in direct clinical trial costs, according to the Tufts Center for the Study of Drug Development. These numbers show why speed and control matter more than ever, as drug development continues getting more complex and expensive.

    Dec 19, 2025